DaVita Inc. (NYSE:DVA) Stake Boosted by Invesco Ltd.

Invesco Ltd. boosted its stake in DaVita Inc. (NYSE:DVA - Free Report) by 20.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,589,545 shares of the company's stock after purchasing an additional 275,284 shares during the quarter. Invesco Ltd. owned about 1.94% of DaVita worth $237,716,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Janus Henderson Group PLC increased its position in DaVita by 8.5% during the 3rd quarter. Janus Henderson Group PLC now owns 5,847 shares of the company's stock worth $958,000 after purchasing an additional 457 shares in the last quarter. National Bank of Canada FI boosted its position in DaVita by 14.6% during the 3rd quarter. National Bank of Canada FI now owns 38,232 shares of the company's stock worth $6,267,000 after purchasing an additional 4,876 shares during the period. MML Investors Services LLC raised its position in DaVita by 1.3% in the third quarter. MML Investors Services LLC now owns 5,300 shares of the company's stock valued at $869,000 after purchasing an additional 68 shares during the period. Nomura Asset Management Co. Ltd. boosted its position in shares of DaVita by 0.4% in the third quarter. Nomura Asset Management Co. Ltd. now owns 28,790 shares of the company's stock worth $4,720,000 after buying an additional 117 shares during the period. Finally, M&T Bank Corp raised its holdings in shares of DaVita by 4.2% during the 3rd quarter. M&T Bank Corp now owns 3,534 shares of the company's stock valued at $579,000 after buying an additional 143 shares during the period. 90.12% of the stock is currently owned by institutional investors and hedge funds.

DaVita Stock Performance

Shares of NYSE:DVA traded down $0.55 during trading hours on Thursday, hitting $140.96. The stock had a trading volume of 352,642 shares, compared to its average volume of 829,438. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. The stock's fifty day simple moving average is $150.47 and its 200 day simple moving average is $156.34. The firm has a market capitalization of $11.28 billion, a price-to-earnings ratio of 13.10, a PEG ratio of 1.07 and a beta of 1.04. DaVita Inc. has a 1-year low of $125.64 and a 1-year high of $179.60.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, beating analysts' consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. Sell-side analysts anticipate that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on DVA. Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a research report on Friday, February 21st. Barclays lifted their target price on DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research report on Tuesday, February 18th. StockNews.com upgraded DaVita from a "hold" rating to a "buy" rating in a report on Thursday, April 10th. Finally, Cowen reissued a "hold" rating on shares of DaVita in a research report on Tuesday, February 18th. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $166.33.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.